PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
28790099-0	2017	GSK2586184, a JAK1 selective inhibitor, in two patients with ulcerative colitis.	GSK2586184	0-10	Janus kinase 1	Homo sapiens	14-18
28790099-7	2017	The JAK1 selective inhibitor GSK2586184 was well tolerated and induced clinical and endoscopic response in two patients with moderate-to-severe UC.	GSK2586184	29-39	Janus kinase 1	Homo sapiens	4-8
28158411-8	2017	GSK2586184, a Janus kinase 1 selective inhibitor, induced clinical and endoscopic response in ulcerative colitis; however, the study was discontinued at an early stage due to liver toxicity observed in systemic lupus patients receiving the drug.	GSK2586184	0-10	Janus kinase 1	Homo sapiens	14-28
26785220-0	2016	Investigation of selective JAK1 inhibitor GSK2586184 for the treatment of psoriasis in a randomized placebo-controlled phase IIa study.	GSK2586184	42-52	Janus kinase 1	Homo sapiens	27-31
27055521-0	2016	Safety, tolerability, efficacy and pharmacodynamics of the selective JAK1 inhibitor GSK2586184 in patients with systemic lupus erythematosus.	GSK2586184	84-94	Janus kinase 1	Homo sapiens	69-73
27055521-1	2016	We aimed to evaluate the pharmacodynamics, efficacy, safety and tolerability of the JAK1 inhibitor GSK2586184 in adults with systemic lupus erythematosus (SLE).	GSK2586184	99-109	Janus kinase 1	Homo sapiens	84-88
26785220-1	2016	BACKGROUND: GSK2586184 is a selective oral Janus kinase (JAK)1 inhibitor being evaluated as a treatment for moderate-to-severe plaque-type psoriasis.	GSK2586184	12-22	Janus kinase 1	Homo sapiens	43-62
25724932-0	2015	DRESS syndrome and reversible liver function abnormalities in patients with systemic lupus erythematosus treated with the highly selective JAK-1 inhibitor GSK2586184.	GSK2586184	155-165	Janus kinase 1	Homo sapiens	139-144